Although there is a correlation between PD-L1 expression and immunotherapy response rate in pan-cancer analysis, many PD-L1-expressing patients are resistant to ICI, and some patients without PD-L1 expression benefit from treatment43. The gene discussed is CD274; the disease is cancer.